March 20 (Reuters) - Prothena Corporation Plc:
* PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES
* PROTHENA CORPORATION - PROTHENA TO RECEIVE A $100 MILLION UPFRONT PAYMENT AND A $50 MILLION EQUITY INVESTMENT BY CELGENE
* PROTHENA CORPORATION- COLLABORATION INCLUDES POTENTIAL LICENSE PAYMENTS, MILESTONES, PLUS ADDITIONAL ROYALTIES ON SALES FROM LICENSED PROGRAMS FOR CO
* PROTHENA CORPORATION PLC - CELGENE WILL SUBSCRIBE TO ABOUT 1.2 MILLION OF PROTHENA'S ORDINARY SHARES AT $42.57 PER SHARE Source text for Eikon: Further company coverage:
